Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2014 Dec 3

PMID 25446773

Citations 42

Authors

Amrita V Kamath

Suhasini Iyer

Affiliations

Soon will be listed here.

Abstract

Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA approved ADCs on the market and over 30 ADCs in the clinical pipeline against a number of different cancer types. The structure of an ADC is very complex with multiple components and considerable efforts are ongoing to determine the attributes necessary for clinical success. Understanding the pharmacokinetics of an ADC and how it impacts efficacy and toxicity is a critical part of optimizing ADC design and delivery i.e., dose and schedule. This review discusses the pharmacokinetic considerations for an ADC and tools and strategies that can be used to evaluate molecules at the preclinical stage.

Citing Articles

Simultaneous Quantification of Total Antibody and Conjugated Payload for DS001 in Rat Serum Using a Hybrid Immuno-Capture LC-MS/MS.

Yu X, Li W, Huang W, Xiao B, Long J, Wang Q AAPS J. 2025; 27(1):23.

PMID: 39775231 DOI: 10.1208/s12248-024-01007-4.

Kinetic Modeling of the Antibody Disulfide Bond Reduction Reaction With Integrated Prediction of the Drug Load Profile for Cysteine-Conjugated ADCs.

Weggen J, Gonzalez P, Hui K, Bean R, Wendeler M, Hubbuch J Biotechnol Bioeng. 2024; 122(3):579-593.

PMID: 39688343 PMC: 11808428. DOI: 10.1002/bit.28899.

Application of Pharmacometrics in Advancing the Clinical Research of Antibody-Drug Conjugates: Principles and Modeling Strategies.

Li X, Liu D, Liu S, Yu M, Wu X, Wang H Clin Pharmacokinet. 2024; 63(10):1373-1387.

PMID: 39325307 DOI: 10.1007/s40262-024-01423-x.

Antibody-Drug Conjugates-Evolution and Perspectives.

Chis A, Dobrea C, Arseniu A, Frum A, Rus L, Cormos G Int J Mol Sci. 2024; 25(13).

PMID: 39000079 PMC: 11241239. DOI: 10.3390/ijms25136969.

Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.

Kumari S, Raj S, Babu M, Bhatti G, Bhatti J Arch Pharm Res. 2023; 47(1):40-65.

PMID: 38153656 DOI: 10.1007/s12272-023-01479-6.

References

Mullard A . Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013; 12(5):329-32. DOI: 10.1038/nrd4009. View

Poon K, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O . Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013; 273(2):298-313. DOI: 10.1016/j.taap.2013.09.003. View

Pastuskovas C, Mallet W, Clark S, Kenrick M, Majidy M, Schweiger M . Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos. 2010; 38(12):2309-19. DOI: 10.1124/dmd.110.034330. View

Gorovits B, Alley S, Bilic S, Booth B, Kaur S, Oldfield P . Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 2013; 5(9):997-1006. DOI: 10.4155/bio.13.38. View

Krop I, Beeram M, Modi S, Jones S, Holden S, Yu W . Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28(16):2698-704. DOI: 10.1200/JCO.2009.26.2071. View

Carter P, Senter P . Antibody-drug conjugates for cancer therapy. Cancer J. 2008; 14(3):154-69. DOI: 10.1097/PPO.0b013e318172d704. View

Alley S, Benjamin D, Jeffrey S, Okeley N, Meyer D, Sanderson R . Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008; 19(3):759-65. DOI: 10.1021/bc7004329. View

Junutula J, Flagella K, Graham R, Parsons K, Ha E, Raab H . Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010; 16(19):4769-78. DOI: 10.1158/1078-0432.CCR-10-0987. View

Kaur S, Xu K, Saad O, Dere R, Carrasco-Triguero M . Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis. 2013; 5(2):201-26. DOI: 10.4155/bio.12.299. View

10.

Shen B, Xu K, Liu L, Raab H, Bhakta S, Kenrick M . Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012; 30(2):184-9. DOI: 10.1038/nbt.2108. View

11.

Kung Sutherland M, Walter R, Jeffrey S, Burke P, Yu C, Kostner H . SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013; 122(8):1455-63. DOI: 10.1182/blood-2013-03-491506. View

12.

Glassman P, Balthasar J . Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014; 11(1):20-33. PMC: 3969805. DOI: 10.7497/j.issn.2095-3941.2014.01.002. View

13.

Herbertson R, Tebbutt N, Lee F, Macfarlane D, Chappell B, Micallef N . Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res. 2009; 15(21):6709-15. PMC: 6944432. DOI: 10.1158/1078-0432.CCR-09-0536. View

14.

Flygare J, Pillow T, Aristoff P . Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2012; 81(1):113-21. DOI: 10.1111/cbdd.12085. View

15.

Gibiansky L, Gibiansky E . Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2013; 41(1):35-47. DOI: 10.1007/s10928-013-9344-y. View

16.

Alley S, Zhang X, Okeley N, Anderson M, Law C, Senter P . The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther. 2009; 330(3):932-8. DOI: 10.1124/jpet.109.155549. View

17.

Beck A, Reichert J . Antibody-drug conjugates: present and future. MAbs. 2014; 6(1):15-7. PMC: 7098595. DOI: 10.4161/mabs.27436. View

18.

Bender B, Leipold D, Xu K, Shen B, Tibbitts J, Friberg L . A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014; 16(5):994-1008. PMC: 4147041. DOI: 10.1208/s12248-014-9618-3. View

19.

Chudasama V, Schaedeli Stark F, Harrold J, Tibbitts J, Girish S, Gupta M . Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012; 92(4):520-7. PMC: 3745717. DOI: 10.1038/clpt.2012.153. View

20.

Sliwkowski M, Mellman I . Antibody therapeutics in cancer. Science. 2013; 341(6151):1192-8. DOI: 10.1126/science.1241145. View